This is a preview of subscription content, log in via an institution to check access.
Reference
Cella D, et al. Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study. 2013 Genitourinary Cancers Symposium : abstr. 346, 14 Feb 2013.
Rights and permissions
About this article
Cite this article
Better QOL with pazopanib in RCC. PharmacoEcon Outcomes News 673, 10 (2013). https://doi.org/10.1007/s40274-013-0220-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0220-1